Immunohistochemical expression of H3.3 G34W in 100 giant cell tumors of bone and its diagnostic mimics, including its value in resolving uncommon diagnostic scenarios: A single institutional study at a tertiary cancer referral center, India

Bharat Rekhi; Vinayak Dave; Ashwin Butle; Bhasker Dharavath; Sonali Khetale; Archana K Redhu; Rudransh Singh; Amit Dutt

doi:10.4103/ijpm.ijpm_886_23

Immunohistochemical expression of H3.3 G34W in 100 giant cell tumors of bone and its diagnostic mimics, including its value in resolving uncommon diagnostic scenarios: A single institutional study at a tertiary cancer referral center, India

Indian J Pathol Microbiol. 2024 Feb 12. doi: 10.4103/ijpm.ijpm_886_23. Online ahead of print.

Authors

Bharat Rekhi^{1

2}, Vinayak Dave¹, Ashwin Butle³, Bhasker Dharavath^{3

4}, Sonali Khetale², Archana K Redhu³, Rudransh Singh³, Amit Dutt^{3

4}

Affiliations

¹ Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI) University, Mumbai, Maharashtra, India.
² Department of Molecular Pathology and Translational Medicine, Tata Memorial Centre, Homi Bhabha National Institute (HBNI) University, Mumbai, Maharashtra, India.
³ Department of Integrated Cancer Genomics Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, India.
⁴ Department of HBNI Training School Complex, Maharashtra, India.

PMID: 38391356
DOI: 10.4103/ijpm.ijpm_886_23

Abstract

Background: There can be a diagnostic challenge in differentiating giant cell tumor of bone (GCTB) from its mimics. Lately, histone H3F3A (Histone 3.3) G34W has been identified as a promising immunohistochemical marker.

Aims: This study was aimed at evaluating H3.3 G34W immunostaining in 100 GCTBs, including its value in resolving diagnostic dilemmas.

Materials and methods: Immunohistochemical staining for H3.3 G34W was graded in terms of staining intensity (1+ to 3+) and the percentage of tumor cells showing crisp nuclear staining.

Results: One hundred GCTBs occurred in 58 males and 42 females (M: F ratio = 1.3), of 7-66 years age (average = 31.3, median = 28), commonly in distal femur (26), followed by proximal tibia (17), distal radius (12), proximal humerus (7), metacarpals (7), sacrum (6), proximal fibula (6), and relatively unusual sites (19), including a single multicentric case. Out of 92 GCTBs, wherein H3.3 G34W immunostaining worked, 81 (88.1%) showed positive staining in the mononuclear cells, including tumors with fibrous histiocytoma-like areas, sparing osteoclast-like giant cells, with 3+ staining intensity in 65/81 (80%) tumors. All 7/7 (100%) malignant GCTBs showed positive staining, including the pleomorphic/sarcomatous cells. All 7/7 (100%) metastatic GCTBs showed positive immunostaining. Seven out of 10 post-denosumab treated GCTBs showed positive H3.3 G34W immunostaining in the residual mononuclear cells. None of the other 37 "giant cell-rich" lesions displayed H3.3 G34W immunostaining. Four of 9 GCTBs tested for H3.3 G34W mutation showed positive results.

Conclusions: The diagnostic sensitivity and specificity of H3.3 G34W for GCTB were 88.1% and 100%, respectively. This constitutes one of the first reports from our country, further validating the diagnostic value of H3.3 G34W in differentiating GCTB, including metastatic and malignant forms from its mimics, including small biopsy samples. Its value in various diagnostic dilemmas is presented and utility in identifying residual tumor cells in post-denosumab treated GCTBs is worth exploring.